[Infliximab treatment for Behçet's disease--beginning of the biological drug era].
Namba
Kenichi
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000150:complications* / Q000188:drug therapy*; D015195:Drug Design; D006801:Humans; D000069285:Infliximab; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology; D014605:Uveitis / Q000188:drug therapy* / Q000209:etiology*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab